This page is updated frequently with new Vaccine-related patent applications.
|Method of evaluating glioblastoma multiforme patient applicable to immunotherapy treatment based on dendritic cell tumor vaccines and prognosticating survival rate in glioblastoma mulztiforme patient after treatment|
A method of evaluating if a glioblastoma multiforme (gbm) patient is applicable to be treated with an immunotherapy based on dendritic cell tumor vaccines includes a sample obtaining step to obtain a sample from the gbm patient, a detecting step to detect an expression level of a biomarker, and a comparing step to compare the expression level of the biomarker to a threshold, wherein the gbm patient is applicable to treat with the immunotherapy based on dendritic cell tumor vaccines when the expression level of the biomarker is lower than the threshold. A method of prognosticating a survival rate in the gbm patient after a treatment includes a sample obtaining step, a detecting step, and a comparing step, wherein the gbm patient is determined to have a good prognosis after the treatment when the expression level of the sample from the gbm is lower than the threshold..
China Medical University Hospital
|Chimpanzee adenoviral vector-based filovirus vaccines|
This invention provides vaccines for inducing an immune response and protection against filovirus infection for use as a preventative vaccine in humans. In particular, the invention provides chimpanzee adenoviral vectors expressing filovirus proteins from different strains of ebolavirus (ebov) or marburg virus (marv)..
Glaxosmithkline Biologicals Sa
|Humanized monoclonal antibodies and methods of use|
The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor ccr4. This antibody is derived from mab 1567 and recognizes the same epitope.
The Brigham And Women's Hospital
|Human sperm fibrous sheath (fs) proteins: new target antigens for use in therapeutic cancer vaccines and diagnostic screening and methods of using same|
Cancer vaccines were demonstrated to be promising strategies for cancer treatment; however these strategies are limited by the paucity of target antigens that provoke an effective immune response. The inventors of the present patent application propose that sperm fibrous sheet proteins constitute a new class of potential antigens for use in the development of effective, durable cancer vaccines.
|Antiviral beta-amino acid ester phosphodiamide compounds|
And their pharmaceutically acceptable salts are useful for the inhibition of hiv reverse transcriptase. The compounds may also be useful for the prophylaxis or treatment of infection by hiv and in the prophylaxis, delay in the onset or progression, and treatment of aids.
|Proteins expressed by mycobacterium tuberculosis and not by bcg and their use as diagnostic reagents and vaccines|
The present invention is directed to reagents useful for generating immune responses to mycobacterium tuberculosis and for diagnosing infection and disease in a subject that has been exposed to m. Tuberculosis..
Rutgers, The State University Of New Jersey
|Antibody-mediated disruption of quorum sensing in bacteria|
The invention provides an immunogenic molecular entity and related vaccines that can be used to inhibit gram-positive bacterial quorum sensing, prevent infection or development of a disease condition associated with a gram-positive bacterial infection. The invention also provides methods of inhibiting gram-positive bacterial quorum sensing, and methods of preventing infection or development of a disease condition associated with a gram-positive bacterial infection..
|Smallpox vaccine for cancer treatment|
Disclosed herein are methods and compositions related to therapy for cancer. More specifically, the disclosed methods and compositions are related to the use of smallpox vaccine to induce an effective anti-tumor immune response..
|Recombinant modified vaccinia virus ankara (mva) respiratory syncytial virus (rsv) vaccine|
Provided herein are recombinant modified vaccinia virus ankara (mva) strains as improved vaccines against infection with respiratory syncytial virus (rsv virus) and to related products, methods and uses. Specifically, provided herein are genetically engineered recombinant mva vectors comprising at least one nucleotide sequence encoding an antigenic determinant of an rsv membrane glycoprotein and at least one nucleotide sequence encoding an antigenic determinant of an rsv nucleocapsid protein.
Bavarian Nordic A/s
|Recombinant turkey herpesvirus vaccines and uses thereof|
The present disclosure provides a recombinant viral vector comprising at least one transgene inserted into a marek's disease viral genome for treatment of diseases in poultry. Also provided are immunogenic compositions comprising such recombinant viral vectors and methods for preventing or inhibiting marek's disease in combination with at least a second disease in poultry..
The Texas A&m University System
Capsular polysaccharide solubilisation and combination vaccines
Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol.
Glaxosmithkline Biologicals Sa
New m.tuberculosis vaccines
The present invention is directed to a fusion protein, antigen cocktails and immunological compositions such as vaccines against infections caused by virulent mycobacteria, e.g. By mycobacterium tuberculosis, mycobacterium africanum, mycobacterium bovis, mycobacterium microti, mycobacterium canettii, mycobacterium pinnipedii or mycobacterium mungi.
Statens Serum Institut
Multi-indication mrna cancer immunotherapy
Synthetic bacterial messenger rna can be used to prepare autologous, allogenic or direct nucleic acid cancer vaccines. Cancer cells are transfected either in vitro or in vivo with mrna obtained from dna that encodes an immunogenic bacterial protein.
Vaccines for protection from and treatment of alzheimer's disease
Disclosed herein are dna-based vaccines against amyloid β peptide for use in treating and alleviating alzheimer's disease and related conditions. A dna construct comprising dna encoding one or more amyloid β peptides, such as amino acids 1-11 of aβ, and dna encoding a hepatitis b antigens, is administered with an adjuvant or by electroporation.
Photosensitized trypanosomatids and vaccine compositions thereof
Disclosed herein are methods and compositions for the delivery of polypeptides, including vaccine candidate polypeptides, into mammalian cells comprising the use of photosensitized trypanosomatid organisms. Also disclosed are methods of treatment of trypanosomatid infections comprising administering phthalocyanine compounds or phthalocyanine-treated trypanosomatid microorganisms as vaccines, as well as and polypeptide delivery vectors comprising phthalocyanine-treated trypanosomatid microorganisms..
The Chinese University Of Hong Kong
Bioinformatic processes for determination of peptide binding
This invention relates to the identification of peptide binding to ligands, and in particular to identification of epitopes expressed by microorganisms and by mammalian cells. The present invention provides polypeptides comprising the epitopes, and vaccines, antibodies and diagnostic products that utilize or are developed using the epitopes..
Means and methods for producing neisseria meningitidis capsular polysaccharides of low dispersity
The present invention relates to in vitro methods for producing neisseria meningitidis capsular polysaccharides which have a defined length. The present invention also relates to compositions comprising at least one capsule polymerase, at least one donor carbohydrate and at least one acceptor carbohydrate, wherein the ratio of donor carbohydrate to acceptor carbohydrate is a ratio from 10:1 to 400:1.
Medizinische Hochschule Hannover
Composition comprising branched multipeptide vaccine and vaccine comprising the same
Provided are a branched multi-peptide composition and a vaccine including the same. The branched multi-peptide vaccine according to the present invention is easy to be produced and utilized, thereby being easily applied to the treatment, and is capable of maintaining stable reaction in vivo, such that it is expected that the branched multi-peptide vaccine according to the present invention acts as an effective vaccine.
Industry Foundation Of Chonnam National University
Wherein each symbol is as defined herein, have an immunostimulatory effect and are useful as immunostimulating agents, particularly as adjuvants, and for compositions containing such a compound, and for vaccines containing such a compound and an antigen.. .
Soluble hiv-1 envelope glycoprotein trimers
The present application relates to novel hiv-1 envelope glycoproteins which may be utilized as an hiv-1 vaccine immunogens, antigens for crystallization and for the identification of broad neutralizing antibodies. The present invention encompasses the preparation and purification of immunogenic compositions which are formulated into the vaccines of the present invention..
The Scripps Research Institute
Influenza vaccine and therapy
The present invention is directed generally to m1 polypeptides that can be utilized as vaccines and/or antigens for generation of anti-m1 polypeptide antibodies for prophylactic treatment of individuals who are susceptible to infection by influenza virus. The anti-m1 polypeptide antibodies of the invention are useful for treatment of individuals infected with influenza virus, or useful for prophylactic treatment of individuals who are susceptible to infection by influenza virus, or for immune-suppressed individuals who cannot generate an effective antibody response..
Engen Bio, Llc
Immune enhancing recombinant dengue protein
The invention relates to a method for preventing, ameliorating or treating disease caused by dengue virus in a subject in need thereof comprising administering to the subject a dengue vaccine formulation in combination with a ns3 helicase polypeptide and/or fragment(s) thereof, wherein said method comprises stimulating humoral as well as cell-mediated immunity to the dengue virus in the subject.. .
United States Of America As Represented By The Secretary Of The Army
Methods and materials for producing immune responses against polypeptides involved in antibiotic resistance
This document relates to methods and materials for producing immune responses against polypeptides involved in antibiotic resistance. For example, vaccines against polypeptides involved in antibiotic resistance as well as methods for vaccinating mammals against polypeptides involved in antibiotic resistance are provided..
Mayo Foundation For Medical Education And Research
Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof
The invention provides vaccines containing, as its only active ingredient, a vlp having a cpg oligonucleotide attached thereto and a non-toxic pharmaceutically acceptable carrier or diluent and uses thereof. The invention further provides a pharmaceutical composition comprising a vaccine consisting of a vlp having a cpg oligonucleotide, one or more non-toxic pharmaceutically acceptable carrier or diluent, and a therapeutic agent admixture therewith and uses thereof..
Bullet Biotechnology, Inc.
Thermo-electric heat pump systems
The invention is directed to an energy efficient thermoelectric heat pump assembly. The thermoelectric heat pump assembly preferably comprises two to nine thermoelectric unit layers capable of active use of the peltier effect; and at least one capacitance spacer block suitable for storing heat and providing a delayed thermal reaction time of the assembly.
Ambassador Asset Management Limited Partnership
Two plasmid mammalian expression system
Reverse engineering has offered new ways of studying the pathology of rna viral infections, new more efficient devices of synthesizing recombinant viruses and developing vaccines and also demonstrated the versatility and efficiency of rna dependent rna polymerase rdrp system as an expression system. However, the currently used methods require a repertoire of complex, difficult-to-use tools.
Fusion proteins and combination vaccines comprising haemophilus influenzae protein e and pilin a
The present invention relates to compositions comprising haemophilus influenzae protein e and pilin a. More particularly, the present application relates to fusion proteins and immunogenic compositions comprising protein e and pila, vaccines comprising such immunogenic compositions and therapeutic uses of the same..
Glaxosmithkline Biologicals S.a.
Toll-like receptor-7 and -8 modulatory 1h imidazoquinoline derived compounds
The present disclosure provides novel imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof, and methods of making and using such compounds. The present disclosure also provides tlr7 agonists and tlr7/tlr8 dual agonists, probes, tissue-specific molecules, adjuvants, immunogenic compositions, therapeutic compositions, and self-adjuvanting vaccines including the imidazoquinoline derived compounds, derivatives thereof, analogues thereof, and pharmaceutically acceptable salts thereof.
The University Of Kansas
Compositions and methods for induction of th17 cells
Strains of human-derived bacteria have been obtained from complex fecal samples and shown to induce accumulation of th17 cells in the intestine and promote immune functions. Pharmaceutical compositions containing these bacteria can be used as anti-infectives and as adjuvants in mucosal vaccines..
School Corporation, Azabu Veterinary Medicine Educational Institution
Compositions of vaccines and adjuvants and methods for the treatment of urinary tract infections
This invention describes novel adjuvant compositions and formulations with excellent stability at refrigerated and room temperatures and up to and about 37° c. That can be produced at remarkably low costs.
Sequoia Sciences, Inc
Herpes simplex virus vaccines
The present invention is directed to herpes simplex-2 viruses that may be used in vaccines to immunize patients against genital herpes.. .
The Brigham And Women's Hospital, Inc.
Koi herpesvirus vaccine
The present invention relates to a recombinant koi herpesvirus (khv), methods for the production of such khv, cells comprising such khv and the use of such khv as vector and in vaccines for the prevention and/or therapeutic treatment of a disease in fish caused by koi herpesvirus in carp such as cyprinus carpio carpio or cyprinus carpio koi.. .
Altering the immundominance hierarchy using a dna vaccine expressing conserved regions
The invention provides methods and compositions for eliciting broad immune responses. The methods employ nucleic acid vaccines that encodes highly conserved elements from a virus..
University Of Washington Through Its Center For Commercialization
Avian reovirus vaccines
The present invention relates to novel strains of avian reovirus that were isolated from clinical cases of viral arthritis/tenosynovitis in chickens in the southeast united states. The invention is directed to these novel group 1 and group 2 avian reoviruses, diagnostic assays using antibodies and/or nucleotide- or amino acid-specific components of such viruses, such as the s1 gene encoding the sigma c protein, and to vaccines that protect chickens from disease caused by such viruses..
University Of Georgia Research Foundation, Inc.
Rna interference functions as an antiviral immunity in mammals
The disclosure provides recombinant viral vectors and attenuated viruses and viral vaccines comprising a virus lacking a functional viral rna suppressor of host rnai.. .
The Regents Of The University Of California
Novel immunogens and methods for discovery and screening thereof
The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal t-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof.
Children's Medical Center Corporation
Methods for constructing antibiotic resistance free vaccines
The present invention provides listeria vaccine strains that express a heterologous antigen and a metabolic enzyme, and methods of generating same.. .
The Trustees Of The University Of Pennsylvania
Method for enhancing immune response in the treatment of infectious and malignant diseases
The present invention pertains to a new approach for the treatment of infectious and malignant diseases. The present invention provides new dna and protein vaccines for the treatment of infectious and malignant diseases through enhancing immune response..
Taipei Veterans General Hospital
Dna vaccines and methods for the prevention of transplantation rejection
Methods for preventing, delaying the onset of, or treating rejection of an allograft using a dna vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like bax and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the dna vaccines to a transplant recipient, as described herein, can induce a donor specific tolerogenic response..
Loma Linda University
Human sirpa transgenic animals and their methods of use
The invention relates generally to compositions and methods of using transgenic non-human animals expressing human sirpα that are engrafted with a human hematopoietic system. In various embodiments, the human hematopoietic system engrafted, human sirpα transgenic non-human animals of the invention are useful as systems for the in vivo evaluation of the growth and differentiation of hematopoietic and immune cells, for the in vivo assessment of an immune response, for the in vivo evaluation of vaccines and vaccination regimens, for in vivo production and collection of immune mediators, including human antibodies, and for use in testing the effect of agents that modulate hematopoietic and immune cell function..
Compositions and methods for immunodominant antigens of mycobacterium tuberculosis
Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen m. Tuberculosis and their use in vaccines, therapeutic agents, and various diagnostic tests.
Immport Therapeutics, Inc.
Bluetongue virus recombinant vaccines and uses thereof
The present invention encompasses btv vaccines or compositions. The vaccine or composition may be a vaccine or composition containing btv antigens.
Vaccine adjuvants for cytomegalovirus prevention and treatment
The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for treating human cytomegalovirus using bacterial cell wall components mdp and tri-dap as vaccine adjuvants.
The Johns Hopkins University
Heat inactivated poxvirus improves vaccination results
Compositions including a heat-inactivated poxvirus, such as vaccinia virus, that induces one or more interferons in a vaccine recipient. The compositions may further include one or more live vaccine vectors and non-replicating vaccine components.
Arizona Board Of Regents On Behalf Of Arizona State
Compositions and methods for the treatment of chlamydial infection are disclosed. The compositions provided include polypeptides that contain at least one antigenic portion of a chlamydia antigen and dna sequences encoding such polypeptides.
Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services
Augmentation of cancer and cancer endothelial vaccine immunogenicity by histone deacetylase inhibitors
Disclosed are protocols, procedures and therapeutic compositions useful for augmentation of immunity to cancer and cancer associated endothelial cells by treatment with histone deacetylase (hdac) inhibitors capable of augmenting stimulatory and costimulatory molecules on said cancer vaccines. Additionally, the invention teaches specific concentrations of hdac inhibitors useful for stimulation of in vivo immunity to tumor and tumor endothelial cell targeting vaccines..
Batu Biologics, Inc.